Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19 déc. 2024 08h00 HE
|
Artios Pharma
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...
Modifi Bio Raises Additional $4.3 Million in Seed Funding
16 oct. 2023 07h00 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...
ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
07 oct. 2022 09h00 HE
|
ProLynx LLC
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
08 sept. 2022 08h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11 août 2022 16h15 HE
|
Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April
30 mars 2022 07h00 HE
|
NERx Biosciences
INDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology company led by John Turchi and Katherine Pawelczak, will be presenting on two pre-clinical pipeline drugs that may have...
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
09 déc. 2019 08h30 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
DELFINGEN Industry : Mise à disposition du Document de Référence exercice 2018
29 avr. 2019 14h45 HE
|
DELFINGEN Industry
MISE A DISPOSITION DE DOCUMENTAnteuil, le 29 avril 2019 DELFINGEN Industry annonce ce jour avoir mis à la disposition du public son Document de Référence au 31 décembre 2018. ...
Foncière INEA : Mise à disposition du Document de Référence et du Rapport RSE 2018
15 avr. 2019 12h30 HE
|
Foncière Inéa
Mise à disposition du Document de Référence(valant Rapport Financier Annuel) Exercice 2018 Paris, le 15 avril 2019 Foncière INEA (ISIN : FR0010341032), société d’investissement...
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
10 avr. 2018 09h00 HE
|
ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...